Evaluation of effects of chitosan in preventing hemorrhagic cystitis in rats induced by cyclophosphamide.
ABSTRACT Hemorrhagic cystitis is a common problem following cyclophosphamide or radiation therapy. Chitosan has been shown to be an effective hemostatic agent and promoter of wound healing in animal experiments. We evaluated the safety and efficacy of intravesical chitosan in an animal model of cyclophosphamide cystitis. Hemorrhagic cystitis was induced in female F344 rats by intraperitoneal cyclophosphamide, 100 mg/kg. Chitosan solution (0.3 ml) was instilled intravesically on day 1 (Group 1), on days 1, 3, and 5 (Group 2), or 1 hour after the administration of cyclophosphamide (Group 3). The rats in group 4 were treated with chitosan diluent on day 1 after cyclophosphamide, and the rats in group 5 received intravesical chitosan without cyclophosphamide. Sequential examination revealed decreased mortality and lower incidences of severe bladder bleeding, necrosis and inflammation in Group 3. Treatment delayed until after the appearance of the cystitis, especially repeated treatments, appeared to make the cyclophosphamide-induced changes worse. Used within 1 hour of cyclophosphamide administration, before the cystitis develops, chitosan seemed to have the possibility to inhibit the appearance of hemorrhagic cystitis. In addition to the changes in the bladder, severe changes occurred in the kidneys secondary to cyclophosphamide.
- Chitosan: A new hem astatic 2) Malette WG, Quigley HJ and Addickes ED: Chitosan effect in vascular surgery, tissue culture and tissue regeneration. 55-58..
- the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfami-de and sufosfamide Renal papillary nicrosis: An update. 2045-2049..
Acta Urol. Jpn. 41; 289-296, 1995
EVALUATION OF EFFECTS OF CHITOSAN
IN PREVENTING HEMORRHAGIC
CYSTITIS IN RATS INDUCED
From the Department of Urology, Nagoya City University Medical School
From the Laboratory of Pathology, Aichi Cancer Center Research Institute
From the Department of Pathology and Microbiology, and the Eppley Institute for
Cancer Research, University of Nebraska Medical Center, Omaha, Nebraska, USA
Margaret K. St. John and Samuel M. Cohen
From Division of Urology, in the Department of Surgery, University
of Nebraska Medical Center, Omaha, Nebraska, USA
Rodney J. Taylor
Hemorrhagic cystitis is a common problem following cyclophosphamide or rad.i.ation therapy.
Chitosan has been shown to be an effective hemostatic agent and promoter of wound healing
in animal experiments. We evaluated the safety and efficacy of intravesical chitosan in an animal
model of cyclophosphamide cystitis. Hemorrhagic cystitis was induced in female F 344 rats by
intraperitoneal cyclophosphamide, IOOmg/kg. Chitosan solution (O.3m!) was instilled intravesi-
cally on day 1 (Group I), on days I, 3, and 5 (Group 2), or 1 hour after the administration of
cyclophosphamide (Group 3). The rats in group 4 were treated with chitosan diluent on day 1
after cyclophosphamide, and the rats in group 5 received intravesical chitosan without cyclophos-
phamide. Sequential examination revealed decreased mortality and lower incidences of severe
bladder bleeding, necrosis and inflammation in Group 3. Treatment delayed until after the
appearance of the cystitis, especially repeated treatments, appeared to make the cyclophosphamide-
induced changes worse. Used within 1 hour of cyclophosphamide administration, before the
cystitis develops, chitosan seemed to have the possibility to inhibit the appearance of hemorrha-
gic cystitis. In addition to the changes in the bladder, severe changes occurred in the kidneys
secondary to cyclophosphamide. (Acta Urol. Jpn. 41; 289-296, 1995)
Key Words: Chitosan, cyclophosphamide, hemorrhagic cystitis, bladder instillation.
Chitosan is a collective term applied to
chitin in various stages of deacetylation
and depolymerization. It is composed of
poly-N-acetyl glycosamine units.
material has been shown, when mixed
with whole blood, to form a tenacious
coagulum!). Taking note of this chemi-
eal, several investigators reported that
chitosan was a good hemostatic agent In
animal experimen tsl-3).
a result of
diffuse capillary fragility and bleeding
within the damaged urothelial lining of
the bladder. This clinical entity is a
frequent result of cyclophosphamide ther-
apy or radiation therapy4)
therapeutic modalities for treating this
entity include withholding the causative
agent, catheter drainage, bladder irriga-
tion with normal saline, formalin or silver
nitrate bladder instillations to cauterize
the bladder, transurethral electrocautery,
and occasionally, cystectomy and urinary
diversion in order to control severe hem-
Acta Urol. Jpn. Vol. 41, No.4, 1995
In this study we evaluated the safety
and efficacy of intravesical chitosan in
an animal model of cyclophosphamide-
MATERIALS AND METHODS
Chitosan was kindly supplied by Hoe-
chst-Roussel Pharmacauticals, Inc., (So-
merville, NJ). Sterile chitosan solution
contained 2 mg/ml chitosan and 2 mg/ml
acetic acid. For a placebo, sterile acetic
acid solution (2mg/mI) was also supplied
by Hoechst-Roussel Pharmaceuticals, Inc.,
Cyclophosphamide was purchased from
Elkins-Sinn, Inc. (Cherry Hill, NJ) and
administered dissolved sterile water.
Ninety-one weanling (4 weeks old),
female F344 rats were obtained from Ch-
arles River Breeding Laboratories, Inc ..
(Kingston, NY). Upon arrival, the rats
were weighed and randomly assigned to
an experimental group by a weight strat-
quarantine on their respective control
diets for 5 days prior to study. The rats
were housed 5 or 6 per cage on dry corn-
cob bedding in polycarbonate cages (16
x18x20 inches) with stainless steel wire
bar covers (Lab Products, Inc., Maywood,
NJ). Animal rooms were maintained at
a temperature of 22+3°C and 50+20%
They were kept in
# of rats
T : cyclophoshamide 100mg/kg J.P.
* : chitosan 0.3 ml (2 mg/ml) bladder instillation (nembutal anesthesia).
* : acetic acid 0.3 ml (2 mg/mI) bladder instillation (nembutal anesthesia) .
• : sacrifice 5/group/time.
humidity on a 12-h light/12-h dark cycle.
Food and water were available ad libitum.
Prolab 3000 diet was purchased from Ag-
way, Inc. (St. Mary's, OH).
A preliminary study demonstrated that
a single dose of cyclophosphamide, 100
mg/kg, i.p., produced hemorrhagic cysti-
tis in 100% of the rats.
Figure I shows the experimental design
Group 1 consisted of 20 rats treated with
a single intraperitoneal Injection of
cyclophosphamide at a dose of 100mg/kg
body weight. After 24 hours, transurethral
intravesical instillation of 0.3 ml chitosan
was performed through a 23 G catheter
(Argyl, Medicut "R", Sherwood Medical
Industries. St. Louis, MO) under Nembutal
(Abbott Laboratories, North Chicago,IL.)
anesthesia. Immediately prior to and one
hour after instillation, the bladder con-
tents were emptied by light abdominal mas-
sage so that the duration of exposure to
instilled compounds was consistent. Group
2 consisted of 21 rats injected with cyclo-
phosphamide as in group I. Intravesical
instillation of 0.3ml chitosan was perform-
ed after 24 hours, and after 3 and 5 days.
Group 3 contained 20 rats injected with
cyclophosphamide as in group 1. Intravesi-
cal instillation of 0.3 ml chitosan was per-
formed one hour after injection of cyclo-
phosphamide. Group 4 contained 20 rats
injected with cyclophosphamide as in
Fig. 1. Experimental design
Okamura et aI.: Effects of chitosan
group 1. After 24 hours, 0.3ml (mg/ml) of
acetic acid was instilled into the bladder
instead of chitosan. A fifth group of 10
rats was used as a negative control group
they were treated with intravesical instilla-
tion of 0.3 ml chitosan, but without prior
The rats were sequentially killed as indi-
cated in Fig. 1.
Two to five rats each
from groups 1, 3 and 4 were killed 3,6 and
9 days post-cyclophosphamide injection. In
group 2, 2 to 5 animals were killed 4, 6,
and 9 days post-cyclophosphamide treat-
ment. Five animals in group 5 were killed
on day 3 post-cyclophosphamide treatment.
As occasion demanded, moribund rats
were killed. The last day the rats were
killed was 21 days post-cyclophosphamide
At death, the liver and each kidney were
observed grossly, then carefully removed
and weighed. These organs were placed
directly into formalin fixative.
ders were inflated in situ with fixative,
and a day later were bisected sagittally and
each half cut into 3 to 4 longitudinal strips.
All tissues were embedded in paraffin, sec-
tioned, stained with hematoxylin and eosin
and examined histopathologically.
Experimental data were evaluated statis-
tically on an IBM 3090 mainframe opera-
ting system VM using the Wilcoxon rank
test (for mortality), and Fisher's exact test
1 tail (for macroscopic and microscopic
findings) from the Statistical Analysis Sys-
tem software package (SAS Institute, Inc.,
About 25 % of the rats died before they
were scheduled to because of cyclophos-
phamide toxicity excessive anesthesia. The
rats were killed or found dead as shown in
Table 1. The mortality in each group was
(including moribund killed) 7/20 (35%) in
group 1,8/21 (38%) in group 2,3/20 (15
%) in group 3, 5/20 (25 %) in group 4,
0/10 (0 %) in group 5. Groups 1 and 2
were significantly different from group 5
at p<0.05 (Wilcoxon rank test). In the
groups administered cyclophosphamide, the
mortality was the lowest in group 3 (how-
ever, no significant difference from the
Table 2 summarizes the macroscopic
findings. In groups 1,2 and 4, white nod-
ules, I mm to 5 mm in diameter, were ob-
Table 1. Numbers of rats killed or found dead at different
times after cyclophosphamide injection.
5 6 8
Mb• moribund death
Acta Urol. Jpn. Vol. 41, No.4, 1995
Table 2. Macroscopic findings of kidney and bladders.
Nodule Hydronephrosis Bleeding
Day I, 3, 5
Acid Day I
20 6 (30%)d
21 6 (29%)d 3 (14%)
8 (38%) "d,.
3 20 0 ( 0%)
10 0 ( 0%) (10%)
0 ( 0%)
0 ( 0%)
• Statistical analyses were performed using Fisher's exact test (I-tail),
b CP: cyclophosphamide.
, Significantly different from Group I, p<0.05.
d Significantly different from Group 3, p<0.05.
< Significantly different from Group 3, p<0.OO5.
f Significantly different from Group 3, p<O.OOI.
• Significantly different from Group 4, p<0.05.
h Significantly different from Group 4, p<O.OI.
Table g. Histopathological findings of kidney and bladders.
Acid Day I
10 (50%)" 5 (25%)
II (52%)" 8 (38%)
3 (15%) 3 (15%)
0 ( 0%)
0 ( 0%)
20 12 (60%)h 5 (25%)
0 ( 0%)
0 ( 0%)
10 0 ( 0%)
0 ( 0%)
0 ( 0%) (10%)
0 ( 0%)
• Statistical analyses were performed using Fisher's exact test (I-tail).
h CP: cyclophosphamide.
, 18 rats for bladder.
d Significantly different from Group I, p<0.05.
< Significantly different from Group 3, p<0.05.
f Significantly different from Group 3, p<O.OI.
" Significantly different from Group 3, p< 0.005.
h Significantly different from Group 3, p<O.OOI.
• Significantly different from Group 4, p< 0.05.
j Significantly different from Group 4, p<O.OI.
• Significantly different from Group 4, p< 0.005.·
I Significantly different from Group 4, p<O.OOI.
served in the kidneys in 29 to 35% of the
rats. The nodules were homogeneous and
not encapsulated. A few cases of hydrone-
phrosis were observed in each group. Al-
most all of these cases involved adhesions
of the bladder. Various grades of bladder
hemorrhage were observed in the cyclo-
phosphamide administered groups.
incidence was highest in group 2 (81%) (p
<0.05, p<O.OOI, and p<O.OI, compared to
groups I, 3, 4, respectively) and lowest in
group 3 (20%). The incidence was similar
in groups I and 4 (45% and 40%, re-
spectively). Some rats had adhesions
caused by severe inflammation, and this
was the most common in group 2 (38 %)
(p < 0.05, compared to the other groups).
Macroscopically, no significant findings
were found in the liver.
Table 3 summarizes the histopathologi-
Okamera et at.:' Effects of chitosan
Fig. 2. Severe hemorrhage of bladder in rat
from group 2, involving the entire
thickness of the wall.
face is at the top. H&E, x 40.
Fig. 3. Erosion and ulceration of bladder in
rat from group 2, H&E, x 20
cal findings. In group 2, the incidence of
severe bleeding (52%) (p < 0.05, p < 0.05,
and p < 0.001, compared to groups I, 3, 4,
respectively) (Fig. 2) , erosion or ulceration
(81 %) (p <0.0 I, compared to group 3)
(Fig. 3), and severe necrosis or inflam-
mation (52%) (p<0.05, p< O.OOI, and p<
0.005, compared to groups I, 3, 4, respec-
tively) of the bladder was higher than that
in the other three groups injected with
cyclophosphamide. None of the group 3 ani-
mals had severe necrosis or inflammation.
Simple hyperplasia of the bladder epitheli-
um was seen in all groups. Papillary or
nodular hyperplasia was seen in groups I,
2, and 5 (11%, 11%, and 10%, respectively)
on day 9 or later.
Interestingly, necrotizing papillitis of the
kidneys was seen in only 5% of the rats in
group 3, in contrast to 50 to 60% inciden-
ces in groups I, 2, and 4 (p< 0.005, p<
0.005, and p < 0.001, respectively). The
white nodules in the kidneys were com-
posed of inflammatory granulation tissue
by microscopic examination. Severe hyper-
plasia of the renal pelvis was seen in 15 to
38 % of the rats in the cyclophosphamide-
administered groups, and it was highest in
group 2 (38 %) and lowest in group 3 (15
Because of advanced autolytic changes,
two bladders in group I were excluded
from histopathological examination.
group 5, one rat had multiple stones com-
posed of calcium phosphate.
DISCUSSION AND CONCLUSIONS
Chitosan is a unique hemostatic agent.
Chitosan-induced coagulum does not de-
pend on the normal clotting cascade mech-
anism, and the resulting "clot" does not
undergo retraction like a normal clot. Fur-
thermore, reaction does not occur with al-
bumin, globulin, or platelets. However,
the same coagulum occurs with heparin-
ized blood, washed red cells, and defibrin-
ated blood2). Mallette et aI.2) have shown in
studies involving dacron grafts placed into
dogs that the chitosan coagulum remains
in place around the graft until replaced by
ingrowth of normal smooth muscle, vaso-
vasorum, and nerve fibrils. This is in di-
rect contrast to the extensive fibrotic reac-
tion and fibrosis that occurs around un-
treated dacron grafts! ,2). In another study
involving the effects of chitosan on capil-
lary bleeding, Branden berg et a].3) showed it
to be an effective topical hemostatic agent
when applied to surgically created central
nervous system wounds in cats. In a re-
cent study, Bartone and Adickes6) demon-
strated the effect of chitosan on wounds of
the genitourinary system in dogs. Wounds
were made in the kidney, ureter and penile
foreskin, with decreased fibrosis observed
with chitosan in all tissues studied.
Hemorrhagic cystitis is a fairly common
clinical problem. It is frequently caused
by cyclaphosphamide therapy or radiation
therapy, but may be associated with vesical
malignancy, bladder amyloidosis, or viral
infection. Current therapeutic modalities
are directed at controlling the bleeding